A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

PHASE3CompletedINTERVENTIONAL

Enrollment

1,189

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

January 31, 2008

Conditions

OsteoporosisOsteopenia

Interventions

DRUG

Alendronate

ALN; 70 mg; oral; once weekly

DRUG

Denosumab

60 mg; SC; every 6 months